Falkowski B, Szczepanek‐Parulska E, Krygier A, et al. - Researchers sought to compare interleukin 29 (IL‐29) level between healthy controls (CS) and patients suffering from selected thyroid disorders: Graves’ disease (GD), Hashimoto’s thyroiditis (HT), and subacute thyroiditis (SAT). The GD subgroup vs the CS subgroup was found to have higher IL‐29 level. IL‐29 levels did not differ between the CS and HT or SAT subgroups. In multivariable linear regression analysis, IL‐29 was identified as a statistically significant independent predictor of GD presence following adjustment for TRAb. For the first time ever, increased IL‐29 serum concentrations were found in patients suffering from GD. The likely involvement of IL‐29 in one of the pathogenetic pathways of GD, but no HT and SAT, was suggested. There is a need for future investigations to assess the potential of the protein as a treatment target in GD.